These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 11364918)

  • 21. What they say about nucleotide drugs.
    Posit Aware; 1999; 10(1):44. PubMed ID: 11366523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial agents and chemotherapy: highlights of the 38th Interscience Conference.
    Prescott LM
    Body Posit; 1998 Dec; 11(12):11-2. PubMed ID: 11366134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1592 -- new experimental antiretroviral.
    James JS
    AIDS Treat News; 1996 Aug; (No 253):2-3. PubMed ID: 11363766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA panel fails to recommend adefovir approval. Food and Drug Administration.
    Highleyman L
    BETA; 1999; 12(4):4. PubMed ID: 11367249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DMP-266 and adefovir dipivoxil: 2 new AIDS drugs available to patients without treatment options.
    Baker R
    BETA; 1997 Sep; ():6-7. PubMed ID: 11364709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ABT-387/r early access program expanded further.
    Res Initiat Treat Action; 1999 Dec; 5(5):22. PubMed ID: 11366887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1592 adult compassionate-use program announced.
    AIDS Treat News; 1997 Aug; (No 276):1. PubMed ID: 11364519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [First nucleotide analog against HIV. Lowers viral load also in drug resistance].
    MMW Fortschr Med; 2002 Aug; 144(33-34):60-1. PubMed ID: 12380157
    [No Abstract]   [Full Text] [Related]  

  • 29. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic hepatitis B: a wider range of therapeutic options.
    Prescrire Int; 2007 Aug; 16(90):157-62. PubMed ID: 17724844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upcoming compassionate use programs for two new antiretrovirals will begin this fall.
    Schouten J
    STEP Perspect; 1999; 99(3):16. PubMed ID: 11366864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reevaluating initial therapy.
    Cadman J
    GMHC Treat Issues; 1998 Feb; 12(2):1-5. PubMed ID: 11365217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New drug, new hope.
    TreatmentUpdate; 1998 Mar; 10(1):1-2. PubMed ID: 11365429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glaxo's parsimonious compassion.
    GMHC Treat Issues; 1997; 11(4/5):10. PubMed ID: 11364372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dressing up your virus: a new outfit for HIV.
    Simmons P
    Res Initiat Treat Action; 1998 Aug; 4(5):9. PubMed ID: 11365710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
    AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.